{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-044454","form_type":"8-K","ticker":"AIMD","cik":"0001014763","company_name":"Ainos, Inc.","filed_at":"2026-09-28T12:00:27+00:00","discovered_at":"2026-09-28T12:05:01.553571+00:00","generated_at":"2026-10-12T13:30:46.341721+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ainos licenses VELDONA worldwide to BioPhoenix; $600K upfront, up to ~$10M in fees plus 25% sublicense revenue","bullets":["Ainos granted BioPhoenix an exclusive, worldwide license to VELDONA for Sjögren's disease and thrombocytopenia; $600,000 upfront fee due within 15 business days after delivery conditions.","BioPhoenix pays a one-time first-sublicense fee and 25% of applicable net sublicensing revenue; licensing all 15 additional indications would bring total fees to ~$10.0M.","BioPhoenix funds and executes clinical/regulatory development, reducing Ainos' independent capital needs; Ainos retains platform ownership and prioritizes AI Nose/Chemical Intelligence.","Ainos is barred from competing in the licensed indications worldwide during the term and for 10 years after; term runs to later of last patent expiry or 20 years post-9/24/2026.","VELDONA history: 68 studies (3 Phase I, 63 Phase II, 2 Phase III), 16 indications, ~6,000 participants; Sjögren's had ~497 patients in two Phase III trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-044454","json":"https://secwatch.observer/filing/0001493152-26-044454.json","markdown":"https://secwatch.observer/filing/0001493152-26-044454.md","text":"https://secwatch.observer/filing/0001493152-26-044454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1014763/000149315226044454/0001493152-26-044454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1014763/000149315226044454/form8-k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:30:46.341721+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}